A Mut p53-based bispecific antibody recognizes neoantigens from the TP53 R175H mutation site and TCR-CD3 complex, overcoming the lack of neoantigen presentation and selectively redirecting T cells to recognize Mut p53 tumor cells [78]. The gene discussed is TP53; the disease is neoplasm.